Tolucombi

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

Telmisartan, hydrochlorothiazide

Доступно од:

Krka, d.d., Novo mesto

АТЦ код:

C09DA07

INN (Међународно име):

telmisartan, hydrochlorothiazide

Терапеутска група:

telmisartan and diuretics

Терапеутска област:

Hypertension

Терапеутске индикације:

Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Резиме производа:

Revision: 11

Статус ауторизације:

Authorised

Датум одобрења:

2013-03-13

Информативни летак

                                57
B. PACKAGE LEAFLET
58
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TOLUCOMBI 40 MG/12.5 MG TABLETS
TOLUCOMBI 80 MG/12.5 MG TABLETS
TOLUCOMBI 80 MG/25 MG TABLETS
telmisartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tolucombi is and what it is used for
2.
What you need to know before you take Tolucombi
3.
How to take Tolucombi
4.
Possible side effects
5.
How to store Tolucombi
6.
Contents of the pack and other information
1.
WHAT TOLUCOMBI IS AND WHAT IT IS USED FOR
Tolucombi is a combination of two active substances, telmisartan and
hydrochlorothiazide in one
tablet. Both of these substances help to control high blood pressure.
-
Telmisartan belongs to a group of medicines called angiotensin II
receptor antagonists.
Angiotensin II is a substance produced in your body which causes your
blood vessels to narrow
thus increasing your blood pressure. Telmisartan blocks the effect of
angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
-
Hydrochlorothiazide belongs to a group of medicines called thiazide
diuretics, which cause your
urine output to increase, leading to a lowering of your blood
pressure.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tolucombi 40 mg/12.5 mg tablets
Tolucombi 80 mg/12.5 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Tolucombi 40 mg/12.5 mg tablets
Each tablet contains 40 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Tolucombi 80 mg/12.5 mg tablets
Each tablet contains 80 mg telmisartan and 12.5 mg
hydrochlorothiazide.
Excipient(s) with known effect
Each 40 mg/12.5 mg tablet contains 57 mg of lactose (as monohydrate)
and 147.04 mg sorbitol (E420).
Each 80 mg/12.5 mg tablet contains 114 mg of lactose (as monohydrate)
and 294.08 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Tolucombi 40 mg/12.5 mg tablets:
White to almost white or pinkish white on one side and pink marbled on
the opposite side of two-layer
biconvex oval tablet, tablet dimensions 15 mm x 7 mm.
Tolucombi 80 mg/12.5 mg tablets
White to almost white or pinkish white on one side and pink marbled on
the opposite side of two-layer
biconvex oval tablet, tablet dimensions 18 mm x 9 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension.
Tolucombi fixed dose combination (40 mg telmisartan/12.5 mg
hydrochlorothiazide and 80 mg
telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose
blood pressure is not adequately
controlled on telmisartan alone.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Tolucombi should be taken in patients whose blood pressure is not
adequately controlled by
telmisartan alone. Individual dose titration with each of the two
components is recommended before
changing to the fixed dose combination. When clinically appropriate,
direct change from monotherapy
to the fixed combination may be considered.
-
Tolucombi 40 mg/12.5 mg may be administered once daily in patients
whose blood pressure is
not adequately controlled by telmisartan 40 mg.
-
Tolucombi 80 mg/12.5 mg may be administered once daily in patients
whose blood pressure is
3
not adequately controlled 
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 24-08-2023
Информативни летак Информативни летак Шпански 24-08-2023
Информативни летак Информативни летак Чешки 24-08-2023
Информативни летак Информативни летак Дански 24-08-2023
Информативни летак Информативни летак Немачки 24-08-2023
Информативни летак Информативни летак Естонски 24-08-2023
Информативни летак Информативни летак Грчки 24-08-2023
Информативни летак Информативни летак Француски 24-08-2023
Карактеристике производа Карактеристике производа Француски 24-08-2023
Информативни летак Информативни летак Италијански 24-08-2023
Карактеристике производа Карактеристике производа Италијански 24-08-2023
Извештај о процени јавности Извештај о процени јавности Италијански 08-04-2013
Информативни летак Информативни летак Летонски 24-08-2023
Информативни летак Информативни летак Литвански 24-08-2023
Карактеристике производа Карактеристике производа Литвански 24-08-2023
Информативни летак Информативни летак Мађарски 24-08-2023
Информативни летак Информативни летак Мелтешки 24-08-2023
Информативни летак Информативни летак Холандски 24-08-2023
Карактеристике производа Карактеристике производа Холандски 24-08-2023
Информативни летак Информативни летак Пољски 24-08-2023
Информативни летак Информативни летак Португалски 24-08-2023
Карактеристике производа Карактеристике производа Португалски 24-08-2023
Извештај о процени јавности Извештај о процени јавности Португалски 08-04-2013
Информативни летак Информативни летак Румунски 24-08-2023
Информативни летак Информативни летак Словачки 24-08-2023
Информативни летак Информативни летак Словеначки 24-08-2023
Карактеристике производа Карактеристике производа Словеначки 24-08-2023
Извештај о процени јавности Извештај о процени јавности Словеначки 08-04-2013
Информативни летак Информативни летак Фински 24-08-2023
Информативни летак Информативни летак Шведски 24-08-2023
Информативни летак Информативни летак Норвешки 24-08-2023
Информативни летак Информативни летак Исландски 24-08-2023
Карактеристике производа Карактеристике производа Исландски 24-08-2023
Информативни летак Информативни летак Хрватски 24-08-2023

Обавештења о претрази у вези са овим производом

Погледајте историју докумената